Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
January 25, 2023
Precigen (PGEN) $75 M offering priced at $1.75
January 18, 2023
bluebird bio (BLUE) prices offering of 20 M shares at $6.00
January 9, 2023
RegMed Investors (RMi) Research Note: News related to JPM23
November 24, 2022
Happy Thanksgiving ... giving thanks and be SAFE!
September 28, 2022
RegMed Investors’ (RMi): What’s up Applied Genetic Technologies (AGTC)?
September 21, 2022
bluebird bio (BLUE) announced the FDA has granted Accelerated Approval of SKYSONA® (elivaldogene autotemcel), also known as eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystro
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at firstname.lastname@example.org.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors